Methylene blue da ciwon daji: sakamakon dakin gwaje-gwaje da shaidar marasa lafiya

Shin methylene blue yana kashe ƙwayoyin ciwon daji? A farantin gwaji, sau da yawa amsar ita ce eh. Wannan amsa tana ba mutane mamaki, don haka tana yaɗuwa sosai. Matsalar ita ce ana ɓoye wata tambaya ta biyu a cikinta: shin methylene blue yana maganin ciwon daji a marasa lafiya? A kan wannan tambayar, wallafe-wallafen bincike suna ba da wata amsa dabam, kuma yawancin ruɗanin da ake samu a intanet ya samo asali ne daga haɗa shirye-shiryen bincike uku da suke amfani da rini ɗaya amma suna gwada hanyoyin sa baki daban-daban.

Ka ɗauke shi a matsayin ra'ayoyi uku masu suna ɗaya. Ra'ayi na farko shi ne magani da yake guba ga ƙari da kansa. Ra'ayi na biyu shi ne sinadarin da haske ke kunna aikinsa, wanda yake zama mai guba ne kawai a inda haske ya sauka. Ra'ayi na uku shi ne rini mai shuɗi da yake taimaka wa likitan tiyata ya gani. Sakamakon ɗaya ba ya zama sakamakon sauran. Da zarar ka fahimci wannan bambanci, rarrabe shaidar yana zama da sauƙi.

Abin da bayanin ƙamus na ciwon daji yake faɗa a zahiri

Bayanin methylene blue a ƙamus na National Cancer Institute ya bayyana wani rini mai shuɗi da aka ƙera, wanda yake ɗaurewa da sassan ƙwayar halitta masu cajin lantarki mara kyau, kamar nucleic acids. A fannin kula da ciwon daji, ya bayyana allurarsa cikin naman tsarin limfa yayin tiyata domin ya rina kumburin limfa da ruwan limfa ke zubewa zuwa gare su, don likitan tiyata ya gano su. A wani ɓangare dabam, ya ambaci amfani da shi ta jijiya wajen aikin redox a methemoglobinemia.

Wannan bayanin bai lissafa methylene blue a matsayin tabbataccen maganin ciwon daji ba. Samuwar hanyar haɗi ta neman gwaje-gwaje a shafin wani abu ne da aka saba sakawa a ƙamus, ba hukunci kan tasirin magani ba. Idan wani ya kawo shafin NCI a matsayin hujjar cewa an amince da methylene blue don maganin ciwon daji, to ya fahimci nau'in bayanin da ƙamus yake bayarwa ba daidai ba.

Kashewa kai tsaye ba tare da haske ba: ƙwayoyin halitta eh, marasa lafiya a'a

Binciken da aka fi ambato don bayyana hanyar aikin shi ne bita kan methylene blue a matsayin madadin mai ɗaukar electron a mitochondria. Shawarar da ya gabatar a taƙaice take. Methylene blue yana karɓar electrons daga NADH kusa da complex I, yana miƙa su zuwa cytochrome c, yana tsallake sassan sarkar numfashin ƙwayar halitta da suka lalace. A ƙwayoyin halitta da aka raina a dakin gwaje-gwaje, wannan sauyi yana ƙara amfani da oxygen, yana rage glycolysis da samar da lactate, yana kuma tura tsarin sarrafa sinadarai da makamashi ya koma wajen oxidative phosphorylation.

Game da glioblastoma, gwajin da wannan ya dogara da shi ya yi amfani da layukan ƙwayoyin ƙari da aka raina. Ƙwayoyin da aka yi wa magani sun nuna juya sauyin Warburg, raguwar saurin ninkuwa, kunna siginar damuwar ƙarancin makamashi ta hanyar AMPK, da tsayawa a S-phase na zagayowar ƙwayar halitta. Daga nan ne ikirarin cewa methylene blue yana juya tasirin Warburg ya samo asali. Wannan gaskiya ne, amma ya takaita ga farantan gwaji.

Ba a cika ambaton gwajin bibiyar da yake da muhimmanci ba. Lokacin da wannan rukunin masu bincike ya koma kan ɓeraye masu ɗauke da dashen glioblastoma na mutum, ya kuma ba su methylene blue da zai yaɗu a jiki, hanyar aikin da aka ba da shawara ba ta kunna ba, kuma ƙarin bai ragu ba. Akwai tsofaffin alamomin sakamako daga dabbobi, ciki har da rahoton 1989 kan ɓeraye a samfuran ascites da leukemia wanda ya nuna raguwar saurin girman ƙari, amma bayanan da aka jera a ma'ajiyar bincike ba su da cikakkun bayanan hanyar gwaji da mai karatu na yau yake buƙata. Babu wani abu a wannan ɓangaren bincike da ya kai ga gwajin ɗan adam mai rukunin kwatantawa na methylene blue mai yaɗuwa a jiki a matsayin mai kashe ƙari. Ilimin sinadarai da yake bayan yadda methylene blue ke jigilar electrons yana bayyana dalilin da ya sa tasirin ya dogara da yanayi, ba dalilin da ya sa marar lafiya ya kamata ya sa ran samun sa ba.

Akwai kuma shaidar taka-tsantsan daga ilimin guba. Wani bincike na National Toxicology Program na shekara biyu ya ba manyan ɓeraye da ƙananan ɓeraye sinadarin ta bututun ciki, ya kuma gano ƙarancin jini mai alaƙa da adadin da aka bayar, tare da ƙaruwar ƙarin tsibirorin ƙwayoyin pancreas da na ƙaramar hanji a dabbobin. Ayyukan dakin gwaje-gwaje kan lalacewar DNA da ƙarafa ke shiga tsakani wajen haddasawa ba tare da haske ba suna nuna irin wannan bukatar taka-tsantsan. Babu ɗaya daga cikin waɗannan da ya tabbatar da haɗari ga ɗan adam a wani takamaiman matakin samun sinadarin, amma suna hana gajeriyar ƙa'idar cewa dole rini mai aikin redox ya zama marar illa saboda an daɗe ana amfani da shi. Cikakken bayanin yana tare da tarihin amincin methylene blue.

Jinyar photodynamic: rini ɗaya, hanyar sa baki dabam

Jinyar photodynamic da methylene blue ba magani ba ne da ake yaɗawa a jiki sannan a ƙara haske a matsayin ƙarin abin ado. Hanya ce ta jinya a wani takamaiman wuri: ana sanya rini cikin ko a kan wurin da ya samu matsala, sannan a haska shi da tsawon raƙuman haske da rinin yake sha, wanda ke samar da singlet oxygen da radicals masu lalata naman da yake kusa a cikin tazarar micrometers. Lambobin guba ba tare da haske ba da lambobin lokacin haskawa na iya bambanta har sau goma, don haka ambaton kashe ƙwayoyin halitta a farantin gwaji ba tare da bayyana adadin hasken da aka yi amfani da shi ba ba shi da ma'ana.

Shaidar ɗan adam a nan ba ta da yawa kuma ta takaita ga wurin da aka yi jinyar. Mafi ƙarfi daga cikin ƙananan alamomin sakamako yana cikin nodular basal cell carcinoma, inda wani binciken da aka tsara aka kuma bibiyi gaba ya yi jinyar marasa lafiya 20 da rini a saman fata, da rini a cikin manyan wuraren cutar, sannan haske. Ya ba da rahoton cikakkiyar amsa ta asibiti a 11 cikin 17 da suka kammala a watanni shida, tare da gwajin samfurin nama a inda ya zama dole. Babu rukunin kwatantawa da aka ware ta bazuwar zaɓi. Bayan wannan akwai rahotannin lokuta kaɗan, kamar dawowar ciwon daji na bututun abinci guda uku da aka bibiyi mutuwar nama a wurin, da kuma rahoton mutum ɗaya mai Kaposi sarcoma wanda aka kuma yi amfani da toluidine blue, don haka ba za a jingina tasirin ga methylene blue kaɗai ba.

Duk sauran abin da aka saba ambato bincike ne kafin gwaji a ɗan adam. Wani bita mai tsari na 2023 kan aikin photodynamic na methylene blue ya sami binciken dabbobi goma kacal da suka cika ƙa'idojin shiga. Sun haɗa da samfuran ciwon daji na babban hanji da dubura, melanoma, da na nono, da sauransu, kuma bitar ta bayyana fannin a matsayin bincike kafin gwaji a ɗan adam. Dashen ƙarin babban hanji da dubura da aka yi wa allura a wurin sannan aka haska sun nuna yawan lalacewa mai yawa a wurin a cikin ɓeraye. Ayyukan kan mafitsara, baki da melanoma suna ba da rahoton rasa ikon rayuwa, mutuwar ƙwayoyin halitta ta apoptosis, ko raguwar kama dashen ƙari a layukan ƙwayoyin halitta da dabbobi, ba amsar ƙarin marasa lafiya ga magani ko tsawon rayuwarsu ba. Jinyar haske a wurin wata matsala ta fata ba ta bayyana komai game da shan wani ruwan sinadari don ciwon daji da ya yaɗu zuwa wasu sassan jiki. Sun bambanta wajen hanyar ba da sinadarin, adadinsa a inda aka nufa, haske, nau'in ƙari da ma'aunin sakamako.

Shuɗin tiyata: an tabbatar da amfaninsa, amma ma'aunin sakamakon ba shi ne ake nema ba

Fannin da yake da yawan binciken ɗan adam na gaske yana gwada taimakon gani, ba kashewa ba. A tiyatar nono, wani gwajin kwatanta methylene blue da patent blue ta bazuwar zaɓi a marasa lafiya 142 ya auna gano kumburin limfa na farko da ruwan limfa daga ƙari ke zuwa gare su, ba raguwar ƙari ba. Ya sami adadin ganowa kusan kashi 61 cikin ɗari idan aka kwatanta da kashi 68 cikin ɗari, ba tare da bambanci mai muhimmanci a ƙididdiga ba. Wani ƙaramin gwajin bazuwar zaɓi na marasa lafiya 60 ya gwada rini kaɗai da rini tare da radiocolloid wajen daidaiton ganowa da adadin sakamakon da ya ce babu cuta alhali akwai. A nan ma ma'aunin sakamakon shi ne gano kumburin limfa, ba maganin ciwon daji ba.

Binciken ciki da na'urar endoscopy yana ba da labari iri ɗaya. Wani gwajin bazuwar zaɓi na marasa lafiya 165 masu ulcerative colitis ya kwatanta chromoendoscopy da methylene blue da aka shafa da colonoscopy na al'ada wajen gano sauye-sauyen nama kafin su zama ciwon daji, ya kuma sami ƙarin irin waɗannan wurare da aka gano. Wani binciken tantancewa na mataki III na marasa lafiya 1,205, da aka yi amfani da rini na sha mai nufin babban hanji, ya auna adadin gano adenoma, wanda ya tashi daga kusan kashi 48 zuwa 56 cikin ɗari, ba tare da ikirarin magani ba. Wani binciken yiwuwar aiwatarwa na marasa lafiya goma sha biyu ya yi amfani da rini ta jijiya tare da ɗaukar hotuna da hasken kusa da infrared don ganin bututun da ke kai fitsari daga koda zuwa mafitsara yayin tiyatar ciwon daji a ƙugu. Ya ba da rahoton cewa an ga bututun biyu a kowane mutum. Taimako ne mai amfani ga tiyata, amma ba shaida ba ce cewa rinin ya rage wani ƙari. Jagora kan yadda ake karanta binciken methylene blue yana nan ne musamman saboda ana ambaton ma'aunan ganowa kamar dai su ne ma'aunan magani.

Jadawalin bincike: ƙari, samfurin gwaji, hanyar bayarwa, da ma'aunin sakamakon da aka auna a zahiri

Ka karanta ginshiƙin ma'aunin sakamako daga sama zuwa ƙasa kafin karanta kowace kanun labari. Idan ma'aunin shi ne lactate ko ikon rayuwar ƙwayoyin halitta, binciken ba zai iya goyon bayan ikirarin ƙarin rayuwa ba. Idan ma'aunin shi ne ganowa, ba zai iya goyon bayan ikirarin magani ba.

Tsare-tsaren intanet: tabbatar da haɗin sinadaran, nau'in ciwon daji, da sakamakon

Hanyoyin intanet masu sunaye yawanci suna haɗa methylene blue da maganin ƙwayoyin cuta masu rayuwa a jikin wani, kamar fenbendazole ko ivermectin, wani lokaci kuma a ƙara azumi, a haɗa su da labaran marasa lafiya. Kowane ɓangare yana buƙatar bincike iri ɗaya guda uku: an binciki wannan takamaiman haɗin ne, a wane ciwon daji, kuma da wane sakamako da aka auna?

Ba a gano wani gwaji mai rukunin kwatantawa na sanannen haɗin nan, methylene blue da fenbendazole da ivermectin tare da azumi ko ba tare da shi ba. Rahoton baya-bayan nan da ya fi kusanci da wannan yana saɓa wa labarin. Wani rahoton 2026 kan melanoma da ya yaɗu zuwa wasu sassan jiki ya bayyana mutum mai shekara 74 wanda ya sha ivermectin, fenbendazole, methylene blue da wasu kari da yawa da kansa bayan ya ƙi jinyar da za ta shafi duk jiki. Hotunan bincike da DNA na ƙari da yake yawo a jini sun inganta da farko, sannan suka tabarbare har cutar ta ci gaba. Marubutan sun ɗauki raguwar ƙari da tsarin garkuwar jiki ya haddasa da kansa a matsayin bayani da aƙalla yake da yiwuwa daidai da sauran, saboda yawan sauye-sauyen gado a ƙarin ya yi matuƙar yawa. Marar lafiya ɗaya ba tare da rukunin kwatantawa ba, wanda ya yi amfani da abubuwa da yawa a lokaci guda kuma ba a tabbatar da yadda ya bi tsarin shan su ba, ba sakamakon wani tsarin jinya ba ne.

Sauran ikirarin da suke kewaye da wannan ba su fi zama hujja ba. An janye wani jerin rahotannin marasa lafiya uku kan fenbendazole da aka yaɗa sosai a Janairu 2026 saboda wani rikicin muradu da ba a bayyana ba, wanda mujallar ta ce zai shafi yadda ake fassara sakamakon. Wani binciken ivermectin tare da maganin da ke hana checkpoint a ciwon daji na nono na triple negative yana da rukuni ɗaya, har yanzu yana ɗaukar mahalarta kuma babu sakamakon da aka wallafa. Babu methylene blue, babu fenbendazole, kuma babu azumi a cikinsa. Azumi kansa ya kamata ya kasance a rukuni dabam: wani gwajin bazuwar zaɓi na marasa lafiya 131 kan tsarin abinci mai kwaikwayon azumi a lokacin da ake ba da chemotherapy kafin babban magani a ciwon daji na nono na HER2 negative ya auna guba da alamomin amsa. Akwai kuma ƙaramin gwajin marasa lafiya 44 masu ciwon daji na nono a fanni makamancin wannan. Waɗannan bincike ne kan abin da ake ƙara wa chemotherapy, da ma'aunan amsa, ba hujjar ƙarin rayuwa ta tsarin rini da magungunan ƙwayoyin cuta masu rayuwa a jikin wani ba. Kuma babban gwajin azumi na ciwon daji na babban hanji da dubura ya wallafa tsarin gudanar da gwajinsa kawai ya zuwa yanzu. Bayanan abin da binciken azumi ya gwada a zahiri suna taimaka wa rukunonin su kasance dabam.

Labaran marasa lafiya sun cancanci tausayi, amma har yanzu suna cikin matakin shaida mafi rauni. Labaran sun fi fitowa daga waɗanda suka rayu suka wallafa, suna barin bayanin jinyar al'ada da ake yi a lokaci guda, kuma ba sa nuna jimillar mutanen da suka gwada hanyar. Labari na iya sa a shirya gwaji. Ba zai iya maye gurbin gwaji ba.

Wata shawara ta ƙarshe mai amfani ga marasa lafiya da suke ƙarƙashin kulawar ciwon daji tuni. Methylene blue ba ƙarin abu ba ne da ba shi da tasiri. Amfani da aka amince da shi shi ne methemoglobinemia da aka samu, ƙarƙashin kulawar ƙwararru, kuma yana hana aikin monoamine oxidase type A a matakan taro na nanomolar, wanda yake haifar da hulɗar da aka rubuta tsakaninsa da magungunan damuwa masu tasiri kan serotonin. Duk wanda yake tunanin amfani da shi tare da jinyar ciwon daji ya kamata ya fara kawo takamaiman samfurin, adadin da yake tunanin amfani da shi, da cikakken jerin magungunansa ga ƙungiyar kula da ciwon daji, saboda tarihin gwaje-gwajen da ke sama bai ba da wani dalilin ƙarin rayuwa da zai sa a amince da ƙarin haɗari ba.

Yadda za a yi amfani da wannan shaida

Duk wanda yake fama da ciwon daji kuma yake karantawa game da methylene blue ya kamata ya yi tambayoyi huɗu game da kowane bincike da aka ambata. Shin an yi amfani da haske ne ko ba a yi ba, domin kashewa ta photodynamic ba ta hango kashewa ta sinadarin da ya yaɗu a jiki. Shin samfurin gwajin farantin gwaji ne, dabba, ko marasa lafiya da aka raba ta bazuwar zaɓi, domin na ƙarshe ne kawai zai iya nuna amfanin ga marasa lafiya. Shin ma'aunin sakamakon ganowa ne, mutuwar nama a wurin, ko rayuwa, domin na ƙarshe ne kawai yake amsa tambayar magani. Kuma shin haɗin da aka gwada shi ne wanda ake sayarwa, a nau'in ciwon daji ɗaya, domin aro sakamakon azumi don goyon bayan tsarin amfani da rini kuskuren haɗa rukunoni ne.

Bisa shaidar da ake da ita yanzu, methylene blue abin dogaro ne na bincikar tsarin sarrafa sinadarai da makamashi a dakin gwaje-gwaje, sinadarin da haske ke kunna aikinsa a wani takamaiman wuri wanda har yanzu ake bincika kuma yake da ƙananan alamomin sakamako a fata daga bincike marasa rukunin kwatantawa, da kuma rinin tiyata da aka tabbatar da amfaninsa. Ba a tabbatar da shi a matsayin maganin ciwon daji da yake yaɗuwa a jiki ba, kuma binciken da ke sama bai ba da hujjar tallata wani samfurin sayarwa a matsayin irin wannan magani ba.